What is William Blair's Forecast for MDxHealth Q3 Earnings?

MDxHealth SA (NASDAQ:MDXH - Free Report) - Analysts at William Blair reduced their Q3 2025 earnings per share estimates for MDxHealth in a report released on Thursday, May 15th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.11) per share for the quarter, down from their prior estimate of ($0.09). The consensus estimate for MDxHealth's current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth's Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.33) EPS.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The business had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million.

MDxHealth Price Performance

MDXH stock opened at $2.09 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The company has a market capitalization of $98.83 million, a PE ratio of -1.38 and a beta of 1.32. MDxHealth has a 12-month low of $1.35 and a 12-month high of $3.50. The business's fifty day moving average price is $1.62 and its 200 day moving average price is $1.85.

Institutional Investors Weigh In On MDxHealth

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC acquired a new position in MDxHealth during the 4th quarter worth $25,000. Oppenheimer & Co. Inc. grew its stake in MDxHealth by 100.0% during the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock worth $47,000 after purchasing an additional 10,000 shares in the last quarter. FAS Wealth Partners Inc. grew its stake in MDxHealth by 49.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after purchasing an additional 8,100 shares in the last quarter. XTX Topco Ltd acquired a new position in MDxHealth during the 4th quarter worth $63,000. Finally, Castleview Partners LLC acquired a new position in MDxHealth during the 1st quarter worth $48,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.